BRAF and adenocarcinoma: Anaplastic lymphoma kinase (ALK) gene rearrangement testing was performed in patients with adenocarcinoma who were EGFR negative; BRAF was performed in patients with melanoma, and C-MYC mutations in patients with lymphoma.